Ipamorelin for Fat Loss: Off-Label Use, Evidence, and Monitoring

Is there any human evidence that ipamorelin reduces fat?

No. The only human trial of ipamorelin in patients is a bowel-surgery recovery study, not a fat-loss study.

That phase 2 trial enrolled 117 adults and analyzed 114 after bowel resection. It compared intravenous ipamorelin 0.03 mg/kg twice daily with placebo from day 1 to day 7 [2]. Median time to a tolerated solid meal was 25.3 hours versus 32.6 hours on placebo, a difference that was not significant (p=0.15), and secondary recovery endpoints did not differ [2]. Development was reportedly discontinued after disappointing phase 2 results [1].

What the human studies did measure

The other human study gave 15-minute intravenous infusions of 4.21 to 140.45 nmol/kg to healthy men. Half-life was about 2 hours, and growth hormone peaked about 0.67 hours after the infusion, falling to negligible levels at every dose [3]. It had no efficacy endpoint.

What to watch for

FDA's stated position is that ipamorelin stimulates the GH and IGF-1 axis, so it may carry the risks listed on approved growth hormone labels: neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism, pancreatitis and others, and possibly QT prolongation as with the approved GH stimulator macimorelin. FDA found no data showing it would not [1].

In the ileus trial, low potassium occurred in 12.5% on ipamorelin versus 3.4% on placebo, insomnia in 10.7% versus 5.2%, and high blood sugar at discharge in 14.3% versus 8.6%; serious adverse events were 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications, which FDA said raised safety concerns though the relationship to ipamorelin was unclear [1][2].

That trial assessed safety by monitoring adverse events and laboratory tests [2]. No FDA-approved dose exists for ipamorelin [1].

Regulatory status

FDA lists ipamorelin acetate in category 2, bulk substances that may present significant safety risks, for outsourcing facilities; it was added September 29, 2023 [4][8]. Its stated concerns are possible immunogenicity, unnatural amino acids that complicate characterization, and a report of serious adverse events including death with intravenous use for gastric motility [4].

For state-licensed pharmacies and physicians, ipamorelin appears in the nominated-but-withdrawn table and in none of the three categories on FDA's list updated May 14, 2026 [4][9]. The Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on both forms on October 29, 2024 [5]. WADA prohibits it at all times under S2.2.4 [6][10].